| CARLAT PUBLISHING

The post-test for this issue is available for one year after the publication date to subscribers only. By successfully completing the test you will be awarded a certificate for 2 CME credits. Read More

In emergency departments, psychiatrists are often consulted on patients presenting with agitation. In many cases, these patients are under the influence of substances—either from intoxication or withdrawal. Read More

Treating Co-Occurring Psychiatric Disorders

Just about any psychiatric disorder has a higher rate of addiction comorbidity than in the general population. The rates are even higher in treatment settings—more than 50% of people in addiction treatment settings will have a co-occurring psychiatric problem, and more than 50% in psychiatric settings will typically have a co-occurring Substance Use Disorder. Read More

Here’s the basic framework of Cognitive Behavioral Therapy (CBT), how it can be applied to Substance Use Disorders, and ways to incorporate parts of CBT into your daily addiction treatment practice. Read More

Oral vs Extended-Release Naltrexone for Opioid Use Disorder

Extended-release (XR) naltrexone (Vivitrol) is FDA approved for opioid use disorder and has shown efficacy in several trials. It works best for patients who have already successfully detoxed from opioids and who are highly motivated to abstain. But what about oral naltrexone? Read More

Does Extended-Release Naltrexone Worsen Psychiatric Symptoms?

Extended-release (XR) naltrexone (Vivitrol) is an injectable version of naltrexone that lasts for 4 weeks and is FDA approved for opioid use disorder (OUD). Although effective, there is some concern that XR naltrexone may cause or worsen psychiatric symptoms because of its opioid blockade. Read More

Psychiatry Practice Boosters, Fourth Edition (2023)
Teaches you the key points of 63 of the most clinically relevant studies in psychiatry.
READ MORE

General Psychiatry
Using SAMe In Clinical Practice with Garrett Rossi, MD
Read More

Addiction Treatment
Supervised Drug Consumption Sites
Once controversial, research clearly shows the benefit of these sites, and they have started opening in the United States.
Listen now